Authors

Anjali Gupta, Trinity College of Arts & Sciences
Veeral Saraiya, UNC Gillings School of Global Public Health
April Deveaux, Duke University School of Medicine
Taofik Oyekunle, Duke University School of Medicine
Klarissa D. Jackson, The University of North Carolina at Chapel Hill
Omolola Salako, Lagos University Teaching Hospital
Adetola Daramola, Lagos University Teaching Hospital
Allison Hall, Duke University School of Medicine
Olusegun Alatise, Obafemi Awolowo University
Gabriel Ogun, University College Hospital, Ibadan
Adewale Adeniyi, Federal Medical Centre Nigeria
Omobolaji Ayandipo, University College Hospital, Ibadan
Thomas Olajide, Lagos University Teaching Hospital
Olalekan Olasehinde, Obafemi Awolowo University
Olukayode Arowolo, Obafemi Awolowo University
Adewale Adisa, Obafemi Awolowo University
Oludolapo Afuwape, University College Hospital, Ibadan
Aralola Olusanya, University College Hospital, Ibadan
Aderemi Adegoke, Our Lady of Apostle Catholic Hospital
Trygve O. Tollefsbol, The University of Alabama at Birmingham
Donna Arnett, College of Public Health
Michael J. Muehlbauer, Duke University School of Medicine
Christopher B. Newgard, Duke University School of Medicine
Samuel Ajayi, College of Medicine, University of Ibadan
Yemi Raji, College of Medicine, University of Ibadan
Timothy Olanrewaju, University of Ilorin
Charlotte Osafo, University of Ghana
Ifeoma Ulasi, University of Nigeria
Adanze Asinobi, College of Medicine, University of Ibadan
Cheryl A. Winkler, National Cancer Institute at Frederick
David Burke, University of Michigan, Ann Arbor
Fatiu Arogundade, Obafemi Awolowo University
Ivy Ekem, University of Cape Coast Ghana

Document Type

Article

Publication Date

12-1-2022

Abstract

There is conflicting evidence on the role of lipid biomarkers in breast cancer (BC), and no study to our knowledge has examined this association among African women. We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association of lipid biomarkers—total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides—with odds of BC overall and by subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC) for 296 newly diagnosed BC cases and 116 healthy controls in Nigeria. Each unit standard deviation (SD) increase in triglycerides was associated with 39% increased odds of BC in fully adjusted models (aOR: 1.39; 95% CI: 1.03, 1.86). Among post-menopausal women, higher total cholesterol (aOR: 1.65; 95% CI: 1.06, 2.57), LDL cholesterol (aOR: 1.59; 95% CI: 1.04, 2.41), and triglycerides (aOR: 1.91; 95% CI: 1.21, 3.01) were associated with increased odds of BC. Additionally, each unit SD increase in LDL was associated with 64% increased odds of Luminal B BC (aOR 1.64; 95% CI: 1.06, 2.55). Clinically low HDL was associated with 2.7 times increased odds of TNBC (aOR 2.67; 95% CI: 1.10, 6.49). Among post-menopausal women, higher LDL cholesterol and triglycerides were significantly associated with increased odds of Luminal B BC and HER2 BC, respectively. In conclusion, low HDL and high LDL are associated with increased odds of TN and Luminal B BC, respectively, among African women. Future prospective studies can definitively characterize this association and inform clinical approaches targeting HDL as a BC prevention strategy.

Publication Source (Journal or Book title)

Scientific Reports

Share

COinS